These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 12560198)
21. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. Lazzarin A; Clotet B; Cooper D; Reynes J; Arastéh K; Nelson M; Katlama C; Stellbrink HJ; Delfraissy JF; Lange J; Huson L; DeMasi R; Wat C; Delehanty J; Drobnes C; Salgo M; N Engl J Med; 2003 May; 348(22):2186-95. PubMed ID: 12773645 [TBL] [Abstract][Full Text] [Related]
22. Enfuvirtide, an HIV-1 fusion inhibitor. Jenny-Avital ER N Engl J Med; 2003 Oct; 349(18):1770-1; author reply 1770-1. PubMed ID: 14593994 [No Abstract] [Full Text] [Related]
24. 9th National Retrovirus Conference: new treatments, new choices. Laurence J AIDS Patient Care STDS; 2002 May; 16(5):193-5. PubMed ID: 12055025 [No Abstract] [Full Text] [Related]
25. T-20 small program, CD4 < 50, will enroll November 27 at 3:00 P.M. James JS AIDS Treat News; 2001 Oct; (373):3. PubMed ID: 11768880 [No Abstract] [Full Text] [Related]
27. New-Fill on "hold" and open-label for T-20. Berger DS Posit Aware; 2002; 13(1):64-5. PubMed ID: 12216532 [No Abstract] [Full Text] [Related]
28. Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen. Deeks SG; Lu J; Hoh R; Neilands TB; Beatty G; Huang W; Liegler T; Hunt P; Martin JN; Kuritzkes DR J Infect Dis; 2007 Feb; 195(3):387-91. PubMed ID: 17205477 [TBL] [Abstract][Full Text] [Related]
29. The potential for HIV fusion inhibition. Cammack N Curr Opin Infect Dis; 2001 Feb; 14(1):13-6. PubMed ID: 11979109 [TBL] [Abstract][Full Text] [Related]
30. US FDA approves new class of HIV therapeutics. Robertson D Nat Biotechnol; 2003 May; 21(5):470-1. PubMed ID: 12721558 [No Abstract] [Full Text] [Related]
31. Therapy failure following selection of enfuvirtide-resistant HIV-1 in cerebrospinal fluid. van Lelyveld SF; Nijhuis M; Baatz F; Wilting I; van den Bergh WM; Kurowski M; de Jong D; Hoepelman AI; Wensing AM Clin Infect Dis; 2010 Feb; 50(3):387-90. PubMed ID: 20047481 [TBL] [Abstract][Full Text] [Related]
32. T-20 being called "miraculous". AIDS Patient Care STDS; 2002 Sep; 16(9):462. PubMed ID: 12412581 [No Abstract] [Full Text] [Related]
37. Functional characteristics of the natural polymorphisms of HIV-1 gp41 in HIV-1 isolates from enfuvirtide-naïve Korean patients. Shin Y; Yoon CH; Yang HJ; Lim H; Choi BS; Kim SS; Kang C Arch Virol; 2016 Jun; 161(6):1547-57. PubMed ID: 26997611 [TBL] [Abstract][Full Text] [Related]
38. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. Lalezari JP; Henry K; O'Hearn M; Montaner JS; Piliero PJ; Trottier B; Walmsley S; Cohen C; Kuritzkes DR; Eron JJ; Chung J; DeMasi R; Donatacci L; Drobnes C; Delehanty J; Salgo M; N Engl J Med; 2003 May; 348(22):2175-85. PubMed ID: 12637625 [TBL] [Abstract][Full Text] [Related]